Connable Office Inc. lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 2.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,204 shares of the medical instruments supplier’s stock after selling 351 shares during the quarter. Connable Office Inc.’s holdings in Becton, Dickinson and were worth $2,979,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after acquiring an additional 15,887,611 shares during the period. State Street Corp boosted its stake in shares of Becton, Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares during the period. Northern Trust Corp boosted its stake in shares of Becton, Dickinson and by 4.0% during the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after acquiring an additional 106,966 shares during the period. Finally, Fiera Capital Corp boosted its stake in shares of Becton, Dickinson and by 7.1% during the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock worth $542,825,000 after acquiring an additional 183,372 shares during the period. 86.01% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently commented on BDX shares. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research note on Monday, July 17th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $213.47.

Becton, Dickinson and Company (BDX) opened at $220.00 on Tuesday. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. Becton, Dickinson and Company has a fifty-two week low of $161.29 and a fifty-two week high of $225.23. The company has a market capitalization of $49,889.07, a price-to-earnings ratio of 23.10, a PEG ratio of 1.72 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the previous year, the firm earned $2.12 EPS. Becton, Dickinson and’s revenue was down 2.0% on a year-over-year basis. research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

In other news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now directly owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders have sold a total of 47,038 shares of company stock valued at $9,480,225 in the last three months. 1.40% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/14/connable-office-inc-sells-351-shares-of-becton-dickinson-and-company-bdx.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.